Fintan steele biography template

Prior to joining SomaLogic, Dan was CFO of bio-industrial company OPX Biotechnologies, where he closed $47 million in equity and debt financing;.

Progress towards realization of a personalized medicine vision will require the active cooperation of all stakeholders in the healthcare ecosystem.

DNA can drive diseases such as cystic fibrosis or Tay Sachs, but people with mutations in these very genes can surprisingly be healthy, says Fintan Steele, PhD.

•

Latest Comments

Popular Tags Career Awaken Fund WDPD2024 Rapid Firmness Model Maturity Modelling Environmental Sustainability Access, Use settle down Reuse Advocacy Access WDPD Webinar

Archives

December, 2022
November, 2022
October, 2022
September, 2022
August, 2022
July, 2022
June, 2022
May, 2022
April, 2022
March, 2022
February, 2022
January, 2022
December, 2021
November, 2021
October, 2021
September, 2021
August, 2021
July, 2021
June, 2021

May, 2021
April, 2021
March, 2021
February, 2021
January, 2021
December, 2020
November, 2020
October, 2020
September, 2020
August, 2020
July, 2020
June, 2020
May, 2020
April, 2020
March, 2020
February, 2020
January, 2020
December, 2019
November, 2019
October, 2019
September, 2019
August, 2019
July, 2019
June, 2019

•

US6204248B1 - Pharmaceutical preparations of glutathione and methods of administration thereof - Google Patents

Pharmaceutical preparations of glutathione and methods of administration thereof Download PDF

Info

Publication number: US6204248B1
Authority: US; United States
Prior art keywords: glutathione; gsh; cells; cell; redox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

US09/457,642

Inventor

Harry B. Demopoulos

Myron L. Seligman

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

ANTIOXIDANT PHAMACEUTICALS CORP

Molecular Defenses Holdings LLC

Original Assignee

Antioxidant Pharmaceuticals Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

Filin

•

Significance

Aptamers are now used ubiquitously as binding agents for a broad range of applications. Natural (unmodified) DNA and RNA aptamers have considerably less chemical diversity than protein-based ligands such as antibodies, limiting their utility. Aptamers possessing a single chemical modification have helped bridge this diversity gap. We report the selection and identification of aptamers with two diversity-enhancing chemical modifications that bind and inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9), a representative human therapeutic protein target. The addition of a second modification, especially in certain pairwise combinations, resulted in significant improvements in affinity, ligand efficiency, epitope coverage, metabolic stability, and inhibitory activity. Extensively chemically functionalized aptamers have the potential to become the next generation of nucleic-acid–based ligands.

Keywords: SELEX, modified aptamer, PCSK9, SOMAmer, PSMA

Abstract

The nucleobases comprising DNA and RNA aptamers provide considerably less chemical diversity than protein-based ligands, limiting their versatility. The introduction of novel functional groups at just one of the four bases in modified aptamers has recently led to dramatic improvement in the success r